Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
strategic review
Biotech
Neuphoria nixes social anxiety program after phase 3 flop
Neuphoria’s stock has plummeted 67% after the announcement, dropping from Monday’s close of $15.40 per share to $5 as of 10 a.m. ET today.
Gabrielle Masson
Oct 21, 2025 10:44am
Rome nears end of road with planned layoffs, strategic review
Sep 23, 2025 2:00pm
Galapagos builds island of cell therapies amid pipeline pruning
Jul 24, 2025 10:59am
Sarepta overhaul includes 500 layoffs, gene therapy program cuts
Jul 16, 2025 4:59pm
4 strange cash-saving efforts biotechs are using to stay afloat
Jun 20, 2025 6:00am
Keros culls phase 2 PAH program, 70 staff roles
May 29, 2025 10:10am
